Global hereditary angioedema market is estimated to be valued at USD 3.13 Bn in 2025 and is expected to exhibit a CAGR of 9.6% during the forecast period (2025-2032). Hereditary angioedema is a rare genetic disorder characterized by recurrent episodes of intense subcutaneous or submucosal edema. Symptoms include episodes of swelling in the hands, feet, limbs, face, intestinal tract and airway. The episodes are caused by decreased levels or functioning of C1 inhibitor, which is a serum protein responsible for regulating certain parts of the complement and fibrinolytic systems. Patients with hereditary angioedema experience episodes of edema at least once every 4 weeks on average and commonly require medical intervention for symptom management. Increasing prevalence of disease globally and rising awareness about available treatment options can drive the hereditary angioedema market growth.
Market Dynamics
Increasing research into treatment alternatives, rising prevalence of HAE globally, availability of FDA approved drugs and growing awareness about the disease can drive the hereditary angioedema market growth. However, high costs associated with HAE therapies and lack of awareness in developing countries can hamper the market growth. Development of subcutaneous C1-INH products and oral treatments offers new opportunities for the market players.
Key features of the study
- This report provides in-depth analysis of the global hereditary angioedema market, and provides market size (USD Bn) and compound annual growth rate (CAGR%) for the forecast period (2025–2032), considering 2024 as the base year.
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
- It profiles key players in the global hereditary angioedema market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies.
- Key companies covered as a part of this study include CSL Behring, Sanofi, Takeda Pharmaceutical Company Limited, Orchard Therapeutics plc., Pharming Group N.V., BioCryst Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., Attune Pharmaceuticals, Arrowhead Pharmaceuticals, Inc., Adverum Biotechnologies, Inc., KalVista Pharmaceuticals, and CENTOGENE N.V.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
- Global hereditary angioedema market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global hereditary angioedema market.
Market Segmentation
- By Type Insights (Revenue, USD Bn, 2019 – 2032)
- Hereditary Angioedema Type I
- Hereditary Angioedema Type II
- By Drug Class Insights (Revenue, USD Bn, 2019 – 2032)
- C1 Esterase Inhibitor
- Kallikrein Inhibitor
- Bradykinin Receptor
- Attenuated Androgens
- Others
- By Route of Administration Insights (Revenue, USD Bn, 2019 – 2032)
- Subcutaneous
- Intravenous
- Oral
- By Distribution Channel Insights (Revenue, USD Bn, 2019 – 2032)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Regional Insights (Revenue, USD Bn, 2019 – 2032)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- North America
- Key Players Insights
- CSL Behring
- Sanofi
- Takeda Pharmaceutical Company Limited
- Orchard Therapeutics plc.
- Pharming Group N.V.
- BioCryst Pharmaceuticals, Inc.
- Ionis Pharmaceuticals, Inc.
- Attune Pharmaceuticals
- Arrowhead Pharmaceuticals, Inc.
- Adverum Biotechnologies, Inc.
- KalVista Pharmaceuticals
- CENTOGENE N.V.
Table of Contents
Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Hereditary Angioedema Market, By Type
- Hereditary Angioedema Market, By Drug Class
- Hereditary Angioedema Market, By Route of Administration
- Hereditary Angioedema Market, By Distribution Channel
- Hereditary Angioedema Market, By Region
- Report Description
Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Impact Analysis
- Key Highlights
- Regulatory Scenario
- Product Launches/Approvals
- PEST Analysis
- PORTER’s Analysis
- Merger and Acquisition Scenario
- Epidemiology
- Pipeline Analysis
Hereditary Angioedema Market, By Type, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Hereditary Angioedema Type I
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Hereditary Angioedema Type II
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Introduction
Hereditary Angioedema Market, By Drug Class, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- C1 Esterase Inhibitor
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Kallikrein Inhibitor
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Bradykinin Receptor
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Attenuated Androgens
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Introduction
Hereditary Angioedema Market, By Route of Administration, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Subcutaneous
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Intravenous
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Introduction
Hereditary Angioedema Market, By Distribution Channel, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Introduction
Hereditary Angioedema Market, By Region, 2020 - 2032, (USD Bn)
- Introduction
- Market Share (%) Analysis, 2025,2028 & 2032, (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2021 - 2032, (USD Bn)
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, By Type, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Drug Class, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, (USD Bn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, By Type, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Drug Class, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, (USD Bn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, By Type, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Drug Class, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, (USD Bn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, By Type, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Drug Class, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, (USD Bn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, By Type, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Drug Class, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, (USD Bn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, By Type, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Drug Class, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Country/Region, 2020 - 2032, (USD Bn)
- South Africa
- North Africa
- Central Africa
- Introduction
Competitive Landscape
- CSL Behring
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Sanofi
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Takeda Pharmaceutical Company Limited
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Orchard Therapeutics plc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Pharming Group N.V.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- BioCryst Pharmaceuticals, Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Ionis Pharmaceuticals, Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Attune Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Arrowhead Pharmaceuticals, Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Adverum Biotechnologies, Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- KalVista Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- CENTOGENE N.V.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- CSL Behring
Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
References and Research Methodology
- References
- Research Methodology
- About us
*Browse 32 market data tables and 28 figures on 'Hereditary Angioedema Market' - Global forecast to 2032
EXISTING CLIENTELE
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients


